AbCellera Biologics ABCL Stock
AbCellera Biologics Price Chart
AbCellera Biologics ABCL Financial and Trading Overview
| AbCellera Biologics stock price | 11.32 USD |
| Previous Close | 11.57 USD |
| Open | 11.58 USD |
| Bid | 8.32 USD x 200 |
| Ask | 14.42 USD x 200 |
| Day's Range | 11.14 - 11.8 USD |
| 52 Week Range | 2.75 - 12.15 USD |
| Volume | 4.54M USD |
| Avg. Volume | 8.05M USD |
| Market Cap | 3.67B USD |
| Beta (5Y Monthly) | 1.191 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.54 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.13 USD |
ABCL Valuation Measures
| Enterprise Value | 3.07B USD |
| Trailing P/E | N/A |
| Forward P/E | -15.832168 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 55.43624 |
| Price/Book (mrq) | 3.871409 |
| Enterprise Value/Revenue | 46.341 |
| Enterprise Value/EBITDA | -15.335 |
Trading Information
AbCellera Biologics Stock Price History
| Beta (5Y Monthly) | 1.191 |
| 52-Week Change | 163.55% |
| S&P500 52-Week Change | 18.15% |
| 52 Week High | 12.15 USD |
| 52 Week Low | 2.75 USD |
| 50-Day Moving Average | 7.08 USD |
| 200-Day Moving Average | 4.73 USD |
ABCL Share Statistics
| Avg. Volume (3 month) | 8.05M USD |
| Avg. Daily Volume (10-Days) | 15.16M USD |
| Shares Outstanding | 324.05M |
| Float | 209.09M |
| Short Ratio | 8.29 |
| % Held by Insiders | 21.73% |
| % Held by Institutions | 36.68% |
| Shares Short | 48.32M |
| Short % of Float | 20.41% |
| Short % of Shares Outstanding | 15.77% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -248.83% |
| Operating Margin (ttm) | -1550.048% |
| Gross Margin | -198.87% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -10.38% |
| Return on Equity (ttm) | -17.30% |
Income Statement
| Revenue (ttm) | 66.17M USD |
| Revenue Per Share (ttm) | 0.22 USD |
| Quarterly Revenue Growth (yoy) | -76.29% |
| Gross Profit (ttm) | -131597000 USD |
| EBITDA | -199960000 USD |
| Net Income Avi to Common (ttm) | -164656000 USD |
| Diluted EPS (ttm) | -0.54 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 540.1M USD |
| Total Cash Per Share (mrq) | 1.76 USD |
| Total Debt (mrq) | 135.62M USD |
| Total Debt/Equity (mrq) | 15.14 USD |
| Current Ratio (mrq) | 12.77 |
| Book Value Per Share (mrq) | 2.924 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -94937000 USD |
| Levered Free Cash Flow (ttm) | -46431124 USD |
Profile of AbCellera Biologics
| Country | United States |
| State | BC |
| City | Vancouver |
| Address | 150 W 4th Avenue |
| ZIP | V5Y 1G6 |
| Phone | 604 559 9005 |
| Website | https://www.abcellera.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 562 |
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Q&A For AbCellera Biologics Stock
What is a current ABCL stock price?
AbCellera Biologics ABCL stock price today per share is 11.32 USD.
How to purchase AbCellera Biologics stock?
You can buy ABCL shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AbCellera Biologics?
The stock symbol or ticker of AbCellera Biologics is ABCL.
Which industry does the AbCellera Biologics company belong to?
The AbCellera Biologics industry is Biotechnology.
How many shares does AbCellera Biologics have in circulation?
The max supply of AbCellera Biologics shares is 324.05M.
What is AbCellera Biologics Price to Earnings Ratio (PE Ratio)?
AbCellera Biologics PE Ratio is now.
What was AbCellera Biologics earnings per share over the trailing 12 months (TTM)?
AbCellera Biologics EPS is -0.54 USD over the trailing 12 months.
Which sector does the AbCellera Biologics company belong to?
The AbCellera Biologics sector is Healthcare.
AbCellera Biologics ABCL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26180.46 USD — |
+0.43
|
6.32B USD — | 26049.3 USD — | 26269.85 USD — | — - | 6.32B USD — |
|
US Tech Health Care
IXHC
US
|
1367.82 USD — |
+1.36
|
— — | 1351.7 USD — | 1374.29 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12848.65 USD — |
+0.42
|
— — | 12783.89 USD — | 12893.08 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Developed ex US SC NTR G
NQDMXUSSCGBPN
US
|
1704.47 GBP 2263.58 USD |
0
|
— — | 1704.47 GBP 2263.57 USD | 1704.47 GBP 2263.57 USD | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7285.19 USD — |
+1.34
|
— — | 7209.03 USD — | 7347.6 USD — | — - | — — |
- {{ link.label }} {{link}}
